Insulin-like growth factor I and urokinase-type plasminogen activator bioregulation system as a survival mechanism of prostate cancer cells in osteoblastic metastases: development of anti-survival factor therapy for hormone-refractory prostate cancer

Mol Med. 2000 Apr;6(4):251-67.

Authors

M Koutsilieris¹, C Mitsiades, A Sourla

Affiliation

¹ Department of Experimental Physiology, Medical School, University of Athens, Greece. mkouts@medscape.com

PMID: 10949907
PMCID: PMC1949949

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use
Cell Division / drug effects
Cell Survival / drug effects
Drug Resistance, Neoplasm*
Hormones / pharmacology
Hormones / therapeutic use
Humans
Insulin-Like Growth Factor I / metabolism*
Male
Neoplasm Metastasis / pathology
Osteoblasts / drug effects
Osteoblasts / metabolism
Osteoblasts / pathology*
Prostatic Neoplasms / drug therapy*
Prostatic Neoplasms / metabolism
Prostatic Neoplasms / pathology*
Urokinase-Type Plasminogen Activator / metabolism*

Substances

Antineoplastic Agents
Hormones
Insulin-Like Growth Factor I
Urokinase-Type Plasminogen Activator